Between 1989 and 1990 nine children with neuroblastoma stage IV (according to Evans) have been treated with high-dose [131I-meta]Iodobenzylguanidine (HD-mIBG). The total HD-mIBG dose administered to each child was at mean 699.3 +/- 111 MBq/kg body weight. Prior to (median 28 days) and after (median 50 days) HD-mIBG treatment a diagnostic scan with [123I-meta]Iodobenzylguanidine ([123I-m]IBG) was performed. Scans performed with HD-mIBG were superior to diagnostic scans for the detection of bone lesions in 8/9 children, for the detection of soft tissue lesions in 4/9 children, and for a more precise diagnosis of the primary tumor in 1 child. In 4 children lesions which were primarily identified in the therapeutic scan could be further observed in posttherapeutical examinations.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Analysis of hollow visceral injuries admitted to a level one intensive care unit in South Africa.
S Afr J Surg
December 2024
Division of Surgery, Tygerberg Hospital, Stellenbosch University, South Africa.
Background: Bowel trauma, encompassing injuries to the small and large intestine, represents a significant medical challenge due to its potential for morbidity and mortality. Management of bowel injuries remains surgical, but multiple factors influence the outcome in these patients. This study provides an in-depth analysis of the high-risk features of hollow visceral trauma in the ICU setting and the corresponding mortality rates, shedding light on the critical factors that influence outcomes in these cases.
View Article and Find Full Text PDFThe epidemiological characteristics of major trauma in Pietersburg and Mankweng hospitals, Limpopo province.
S Afr J Surg
December 2024
Trauma and Burns Unit, Inkosi Albert Luthuli Central Hospital, South Africa.
Background: Data on trauma burden and outcome varies amongst the nine South African Provinces. In Limpopo Province there is a paucity of data which this study aimed to quantify and characterise the severe trauma burden in the province.
Methods: A retrospective chart review for all patients with injury severity score (ISS) > 16 over a 6-year period (Jan 2015-Dec 2020) at two central hospitals in Limpopo province.
Time to regional surgical care in rural South Africa.
S Afr J Surg
December 2024
Centre for Global Surgery, Department of Surgical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa.
Background: District hospitals in South Africa have limited surgical capacity and regional hospitals treat most essential surgical conditions. This study aimed to describe the pathway and time to regional hospital surgical care for persons with general surgery conditions (PSC) in South Africa.
Methods: This was a retrospective audit of all persons referred on the Vula Mobile App to the general surgery service at Worcester Regional Hospital (WRH) from 1 January 2019 to 31 December 2019.
Practicing What They Preach: Do Medical Specialty and Subspecialty Conferences Incorporate Physician Wellness Into Their Programs?
Cureus
December 2024
Obstetrics and Gynecology, F. Edward Hebert School of Medicine, Uniformed Services University, Bethesda, USA.
Background: Depending upon their organization and content, medical conferences can enhance wellness or create additional stress for physician attendees. The objective of our study was to examine the degree to which major medical specialty and subspecialty conferences incorporate wellness into their meeting programs.
Methods: We performed a cross-sectional study of major medical conferences occurring in 2023 representing specialties and subspecialties with the greatest number of active physicians.
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.
Front Oncol
January 2025
Sorbonne University and Saint-Antoine Hospital, APHP, Paris, France.
Background: Trifluridine/tipiracil (FTD/TPI) is approved as monotherapy and in combination with bevacizumab for the treatment of patients with refractory metastatic colorectal cancer (mCRC). FTD/TPI plus bevacizumab showed good tolerability in the phase 3 SOLSTICE (first-line) and SUNLIGHT (later-line) trials. This pooled analysis was performed to further characterize the safety of FTD/TPI plus bevacizumab and to compare safety in untreated and previously treated patients with mCRC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!